Translational Session
Advancing the Understanding of Proteinuria and eGFR as FSGS Clinical Trial End Points
October 25, 2024 | 04:30 PM - 06:00 PM
Location: Room 6A, Convention Center
Session Description
The kidney community has benefitted from successful clinical trials in the last decade, including newly approved therapies for people with kidney diseases. Data-sharing efforts transformed the drug development landscape for IgAN by providing a model that could be used to support the design of clinical trials and use of proteinuria as a surrogate end point and basis for approval of new treatments for IgAN. This session highlights a comprehensive international data-sharing and modeling effort across the stakeholder community intended to transform the landscape of drug development for FSGS.
Learning Objective(s)
- Summarize the current landscape of clinical trials in FSGS
- Explain how to establish and measure outcomes in FSGS
- Identify innovative ways to define outcomes of FSGS in large global research networks
Learning Pathway(s)
- Glomerular Diseases
Moderators
Presentations
- Clinical Trials in FSGS: Where Have We Been and Where Are We Heading?
04:30 PM - 04:50 PM
- Regulatory Pathways, Considerations, and the Application of Previous Work in Membranous Nephropathy and IgAN to FSGS
04:50 PM - 05:10 PM
- Modeling Proteinuria and eGFR Slope as Surrogate End Points for FSGS
05:10 PM - 05:30 PM
- Panel Discussion: The Right Outcomes for Trials in FSGS
05:30 PM - 06:00 PM